Laura Yecies discusses Osteoboost, the FDA-cleared wearable using NASA-inspired vibration therapy to combat bone loss in postmenopausal women.

Explore Osteoboost's FDA-cleared wearable delivering targeted vibration therapy to combat bone loss in postmenopausal women.

Grand View Research projects the wearable medical devices market to reach $168.29B by 2030, driven by remote monitoring and home healthcare trends.

CEO Laura Yecies discusses Osteoboost, the FDA-cleared wearable delivering targeted vibration therapy to combat bone loss in postmenopausal women.

CEO Laura Yecies discusses Osteoboost, the FDA-cleared wearable using NASA-inspired vibration therapy to combat bone loss in postmenopausal women.

Discover how Osteoboost is revolutionizing bone health with non-drug therapies in this episode of the Base to Base Biotech podcast.

The journal Medicine highlights Osteoboost as a promising non-drug innovation in osteoporosis care for postmenopausal women.​

The New York Times features Osteoboost as a standout FDA-approved innovation backed by Portfolia, a VC firm leading the charge in women’s health investing.

Explore how Osteoboost’s FDA-cleared wearable uses vibration therapy to reduce bone loss in this insightful review by Dr. Douglas Lucas.​

Femtech Insider reports on Osteoboost Health’s 6th U.S. patent for its FDA-cleared wearable, advancing non-drug osteoporosis treatment with vibration therapy.

Palm Beach Daily News spotlights Osteoboost’s FDA-cleared wearable as a top 2024 health innovation, offering non-drug osteoporosis treatment.

TechRound spotlights Osteoboost’s NASA-inspired vibration therapy, offering drug-free osteopenia treatment for postmenopausal women.